STAT

A Chinese company unveils a powerful new sequencer. But can it compete in the U.S.?

A new genome sequencer from China can generate six terabytes of data in a day — about as much data as a person would use watching Netflix non-stop for half…
A lab worker performs DNA tests at the Beijing Genomics Institute in 2005. The operation evolved into BGI.

Nearly two years ago, the San Diego-based genomics giant Illumina reaffirmed its dominance of the DNA sequencing market when it announced a fast and powerful new machine, called the NovaSeq, that’s since been adopted in labs all over the world.

On Thursday, at a genomics conference in China, a Chinese company called BGI unveiled its own new machine. That machine, the company said, can sequence a whole genome in 24 hours. It can generate six terabytes of sequencing data — about as much data as a person would use watching Netflix nonstop for half a year — over that period. And, again, according to the company, it can do it all with the utmost precision.

All of which could, at the right price, make BGI a very fierce competitor for Illumina — and possibly drive the already-plummeting cost of sequencing down even further.

“It seems that the race is on, and geneticists everywhere are the big winners,” said Christopher Mason, a geneticist at Weill Cornell Medicine.

The race is being closely watched by scientists and clinicians. Cheaper, faster sequencers,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks